(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 3.67% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 5.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.46%.
Bioventus's revenue in 2024 is $555,061,000.On average, 1 Wall Street analysts forecast BVS's revenue for 2024 to be $45,786,432,847, with the lowest BVS revenue forecast at $45,786,432,847, and the highest BVS revenue forecast at $45,786,432,847. On average, 1 Wall Street analysts forecast BVS's revenue for 2025 to be $48,441,810,279, with the lowest BVS revenue forecast at $48,441,810,279, and the highest BVS revenue forecast at $48,441,810,279.
In 2026, BVS is forecast to generate $51,008,891,542 in revenue, with the lowest revenue forecast at $51,008,891,542 and the highest revenue forecast at $51,008,891,542.